MAAT PHARMA: directors' dealings · France · AMF

About MAAT PHARMA

MaaT Pharma is a French clinical-stage biotechnology company listed on Euronext Paris under the ticker MAAT and ISIN FR0012634822. Built around a highly specialized scientific expertise in the microbiome, the company focuses on microbiome-based biotherapies and aims to improve survival outcomes for cancer patients through immune modulation. MaaT Pharma was listed on November 8, 2021, a milestone that enhanced its market visibility and financing capacity. The company’s core platform is its proprietary Microbiome Ecosystem Therapies™ (MET) approach, designed to restore gut microbiome balance and support immune response. Its business is centered on clinical development rather than broad commercial sales, with a strong focus on high-unmet-need oncology and hematology settings. Its lead asset, Xervyteg® (MaaT013), has been developed for severe indications in medically fragile patients, while MaaT033 is currently being evaluated in a potentially pivotal Phase 2b trial. This clinical pipeline reflects a strategy built around scientifically differentiated, value-creating milestones. MaaT Pharma has established a niche position at the intersection of microbiology, immunology and oncology. It stands out as one of the few European listed companies pursuing microbiome-derived therapies for cancer-related complications, in an emerging market that remains early but structurally attractive. A key operational achievement was the completion, with Skyepharma, of what the company described as Europe’s largest manufacturing facility dedicated to Microbiome Ecosystem Therapies. This manufacturing footprint supports both clinical supply and the potential transition toward commercialization. Geographically, MaaT Pharma is headquartered in France but has an international operating profile. Its clinical development, partnerships and regulatory interactions are largely Europe-oriented, while the commercial strategy is being prepared for broader market access. In 2025, the company signed an exclusive license and distribution agreement with Clinigen to support European patient access to Xervyteg® if marketing authorization is obtained, highlighting the company’s step-by-step commercialization model. MaaT Pharma is also followed by several analysts and is widely viewed as a reference French biotech name, with its investment case driven by clinical execution, regulatory progress and financing milestones.